Corresponding Author: Amber Salter, PhD, Division of Biostatistics, Washington University in St Louis, 660 Euclid Ave, Campus Box 8067, St Louis, MO 63110-1093 (firstname.lastname@example.org).
Accepted for Publication: February 19, 2021.
Published Online: March 19, 2021. doi:10.1001/jamaneurol.2021.0688
Correction: This article was corrected on May 3, 2021, to fix an error in the Discussion.
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Salter A et al. JAMA Neurology.
Author Contributions: Dr Salter had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Salter, Fox, Newsome, Li, Costello, Bebo, Rammohan, Cutter, Cross.
Acquisition, analysis, or interpretation of data: Salter, Fox, Newsome, Halper, Li, Kanellis, Bebo, Rammohan, Cutter, Cross.
Drafting of the manuscript: Salter, Halper, Cross.
Critical revision of the manuscript for important intellectual content: Fox, Newsome, Li, Kanellis, Costello, Bebo, Rammohan, Cutter, Cross.
Statistical analysis: Salter, Cutter.
Obtained funding: Bebo, Cutter.
Administrative, technical, or material support: Salter, Li, Kanellis, Bebo, Rammohan, Cutter, Cross.
Supervision: Newsome, Bebo.
Conflict of Interest Disclosures: Dr Salter reports grants from National Multiple Sclerosis Society and is a statistical editor for Circulation: Cardiovascular Imaging during the conduct of the study. Dr Fox reports personal fees from AB Science, Actelion, Biogen, Celgene, EMD Serono, Genentech, Immunic Therapeutics, Novartis, Sanofi, Teva Pharmaceutical, and TG Therapeutics and clinical trial contract and research grant funding from Biogen and Novartis during the conduct of the study. Dr Newsome reports personal fees from Biogen, Novartis, Genentech, Bristol Myers Squibb, EMD Serono, Greenwich Biosciences, BioIncept, Autobahn, Celgene, and MedDay and other support from Biogen, Novartis, Genentech, National Multiple Sclerosis Society, US Department of Defense, and Patient-Centered Outcomes Research Institute paid to their institution outside the submitted work. Dr Li reports personal fees from Biogen and personal fees from Sanofi Genzyme; grants from Sanofi Genzyme, Roche, Novartis, and MS Society of Canada; is emeritus director of the University of British Columbia Multiple Sclerosis/Magnetic Resonance Imaging Research Group, which has been contracted to perform central analysis of magnetic resonance imaging scans for therapeutic trials with Roche and SanofiGenzyme and has received grant support for investigator-initiated studies from Sanofi Genzyme, Novartis, and Roche; and has served on the Progressive Multifocal Leukoencephalopathy–Multiple Sclerosis Steering Committee for Biogen and given lectures, supported by nonrestricted education grants from Academy of Healthcare Learning, Biogen, Consortium of Multiple Sclerosis Centers, and Sanofi Genzyme outside the submitted work. Dr Rammohan reports grants from Biogen, Novartis, Genzyme, Roche Genentech, Alexion, EMD Serono, MedDay Pharma, TG Therapeutics, and US Department of Defense and personal fees from Biogen, Novartis, Genzyme, Roche Genentech, Alexion, and EMD Serono outside the submitted work. Dr Cutter reports personal fees for serving on the data and safety monitoring boards of AstraZeneca, AveXis Pharmaceuticals, BioLineRx, Brainstorm Cell Therapeutics, Bristol Myers Squibb/Celgene, CSL Behring, Galmed Pharmaceuticals, Green Valley Pharma, Horizon Therapeutics, Hisun Pharmaceuticals, Mapi Pharma, Merck, Merck/Pfizer, Opko Biologics, OncoImmune, Neurim Pharmaceuticals, Novartis, Ophazyme, Sanofi-Aventis, Reata Pharmaceuticals, Teva Pharmaceuticals, Viela Bio, Vivus, National Heart, Lung, and Blood Institute (protocol review committee), Eunice Kennedy Shriver National Institute of Child Health and Human Development (obstetric pharmacology research units oversight committee); personal fees from consulting or serving on advisory boards of BioDelivery Sciences International, Biogen, Click Therapeutics, Genzyme, Genentech, GW Pharmaceuticals, Immunic, Klein Buendel, Medimmune/Viela Bio, MedDay, Merck/Serono, Neurogenesis, Novartis, Osmotica Pharmaceuticals, Perception Neuroscience, Recursion/CereXis Pharmaceuticals, Regeneron, Reckover Pharmaceuticals, Roche, and TG Therapeutics; and is President of Pythagoras Inc, a private consulting company. Dr Cross reports personal fees from Biogen, Celgene (Bristol Myers Squibb), EMD Serono, Genentech, Greenwich Biosciences, Janssen, Novartis, and TG Therapeutics outside the submitted work; grants from EMD Serono and Genentech outside the submitted work; and is secretary of the Consortium of Multiple Sclerosis Centers Board of Governors (an elected position), which is a supporter of the COVID-19 Infections in MS Registry, along with National Multiple Sclerosis Society (US) and MS Society of Canada. No other disclosures were reported.
Funding/Support: Support for the COVID-19 Infections in MS Registry is provided by the National Multiple Sclerosis Society, the Consortium of Multiple Sclerosis Centers, and the MS Society of Canada. REDCap at Washington University in St Louis is supported by Clinical and Translational Science Award (CTSA) (grant UL1 TR000448) and Siteman Comprehensive Cancer Center and National Cancer Institute Cancer Center Support Grant (grant P30 CA091842).
Role of the Funder/Sponsor: The National Multiple Sclerosis Society had a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: The COVID-19 Infections in MS Registry had robust participation from health care professionals across North America and we would like to thank all those who contributed information to this effort.
MT , Culpepper
WJ , Campbell
et al; US Multiple Sclerosis Prevalence Workgroup. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology
. 2019;92(10):e1029-e1040. doi:10.1212/WNL.0000000000007035PubMedGoogle ScholarCrossref
Multiple Sclerosis International Federation. Atlas of MS. Published September 2020. Accessed October 24, 2020. http://www.atlasofms.org
N , Fleming-Dutra
K , Gierke
et al; CDC COVID-19 Response Team. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019: United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep
. 2020;69(13):382-386. doi:10.15585/mmwr.mm6913e2PubMedGoogle ScholarCrossref
E , Kister
I , Charvet
et al. COVID-19 outcomes in MS: observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center. Neurol Neuroimmunol Neuroinflamm
. 2020;7(5):e835. doi:10.1212/NXI.0000000000000835Google Scholar
B , Hixon
AM , Tyler
KL , Piquet
AL , Pelak
VS . Neurology and the COVID-19 pandemic: gathering data for an informed response. Neurol Clin Pract
. Published online July 13, 2020. doi:10.1212/CPJ.0000000000000908Google Scholar
PA , Taylor
R , Thielke
R , Payne
J , Gonzalez
N , Conde
JG . Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform
. 2009;42(2):377-381. doi:10.1016/j.jbi.2008.08.010PubMedGoogle ScholarCrossref
MP , De Rossi
N , Schiavetti
et al; Musc-19 Study Group. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol
. Published online January 21, 2021. doi:10.1002/ana.26028Google Scholar
A , Schäfer
M , Gianfrancesco
et al; COVID-19 Global Rheumatology Alliance; COVID-19 Global Rheumatology Alliance Consortium. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis
. Published online January 27, 2021. doi:10.1136/annrheumdis-2020-219498Google Scholar
F ; Discovery French Trial Management Team. Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults. BMJ Open
. 2020;10(9):e041437. doi:10.1136/bmjopen-2020-041437PubMedGoogle Scholar
MP , De Rossi
N , Schiavetti
et al Disease modifying therapies and COVID-19 severity in multiple sclerosis. SSRN Electron J
. Published online June 15, 2020. doi:10.2139/ssrn.3631244
M , Hyrich
KL , Al-Adely
et al; COVID-19 Global Rheumatology Alliance. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis
. 2020;79(7):859-866. doi:10.1136/annrheumdis-2020-217871PubMedGoogle ScholarCrossref